Agoracom Blog Home

Author Archive

Victory Square Technologies $VST.ca $VSQTF Portfolio Company Immersive Announces Upsizing of Its Previously Announced Private Placement Due to Strong Investor Demand $YDX.ca $NTAR.ca $SEV.ca $DBO.ca

Posted by AGORACOM-JC at 5:20 PM on Thursday, April 1st, 2021
Victory Square Technologies VST

  • Announced that further to its news release dated March 29, 2021, its portfolio company Fantasy 360 Technologies Inc. d/b/a Immersive Tech proposes to increase the size of its previously announced non-brokered private placement of subscription receipts of Immersive from $1.5 million due to strong investor demand.
  • Each Subscription Receipt will be sold at a price of $0.35 and be governed by a subscription receipt agreement to be entered between Immersive and an escrow agent to be appointed by Immersive on or prior to the closing date of the SR Offering

VANCOUVER, British Columbia, April 01, 2021 — Victory Square Technologies Inc. (“ Victory Square ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that further to its news release dated March 29, 2021, its portfolio company Fantasy 360 Technologies Inc. d/b/a Immersive Tech (“ Immersive ”) proposes to increase the size of its previously announced non-brokered private placement (the “ SR Offering ”) of subscription receipts of Immersive (“ Subscription Receipts ”) from $1.5 million due to strong investor demand. Each Subscription Receipt will be sold at a price of $0.35 and be governed by a subscription receipt agreement to be entered between Immersive and an escrow agent to be appointed by Immersive on or prior to the closing date of the SR Offering (the “ SR Agreement ”).

In accordance with the SR Agreement, each Subscription Receipt shall be automatically converted without any further action on the part of the holder thereof into one unit of Immersive (each, a “ SR Unit ”) upon the satisfaction of certain escrow release conditions (the “ Escrow Release Conditions ”) including the receipt of conditional approval by Immersive with respect to the listing of the common shares of Immersive (“ Immersive Shares ”) on the Canadian Securities Exchange (the “ CSE ”) and the receipt of a final prospectus of Immersive in the Province of British Columbia. If the Escrow Release Conditions are not satisfied by August 31, 2021, the proceeds of the SR Offering will be returned to the subscribers.

Each SR Unit will consist of one Immersive Share and one-half of one Immersive Share purchase warrant (each whole warrant, an “ SR Warrant ”). Each SR Warrant will entitle the holder thereof to purchase one additional Immersive Share at a price of CAD$0.52 for a period of 24 months following the completion of a going-public transaction by Immersive. Immersive may accelerate the expiry date of the SR Warrants to 30 days following Immersive issuing a news release accelerating the expiry date of the SR Warrants in the event the closing price of the Immersive Shares on the CSE or any equivalent exchange upon which the Immersive Shares trade is equal to or greater than $0.78 per Immersive Share for a period of ten (10) consecutive trading days.

Immersive intends to use the net proceeds from the SR Offering to finance acquisitions, organic growth investments and for general working capital purposes. Finder’s fees may be paid to eligible finders in accordance with the policies of the CSE consisting of a cash commission of up to 6% of the gross proceeds raised under the SR Offering and finder warrants (“ Finder Warrants ”) in an amount up to 6% of the number of Subscription Receipts sold pursuant to the SR Offering. Each Finder Warrant will have the same terms as the SR Warrants.

Closing of the SR Offering is subject to customary closing conditions including, but not limited to, receipt of any required regulatory approvals. The securities being offered under the private placement will be issued pursuant to available exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the later of: (i) the date of issue, and (ii) the date on which Immersive becomes a reporting issuer in any jurisdiction in Canada. The Immersive Shares comprising the SR Units and underlying the SR Warrants will be subject to a contractual lock-up with 25% released from contractual lock-up on the date of conversion of the Subscription Receipts and 75% released 4 months thereafter.

Source: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/758410-victory-square-technologies-inc-portfolio-company-immersive-announces-upsizing-of-its-previously-announced-private-placement-due-to-strong-investor/messages/2310649#message

AGORACOM Small Cap 60: Wildly Successful Partnership With First Tube Media Puts ImagineAR On The Map $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 1:01 PM on Thursday, April 1st, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

AGORACOM Small Cap 60: What Gives Valeo Pharma A Competitive Advantage In The $700M CAD / Year Asthma Market? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:02 PM on Thursday, April 1st, 2021

VIDEO – AI/ML Innovations $AIML.ca $FIRZF Pens Partnerships for Health Gauge, Eyeing FDA Approval for Stateside Launch $PFM.ca $DM.ca $ADK.ca

Posted by AGORACOM-JC at 8:57 AM on Thursday, April 1st, 2021
AI/ML Innovations Inc.

AI/ML Innovations is capitalizing on the burgeoning areas of artificial intelligence (AI) and machine learning (ML), with an initial focus on emerging companies in the digital healthcare space.

Its key subsidiary, Health Gauge, is a leading digital health solutions provider that’s poised to disrupt the traditional healthcare industry by providing AI innovations and services that improve health outcomes, while at the same time reducing costs and stresses on the overburdened healthcare infrastructure.

Its patent-pending solution is a bespoke personal health monitoring & management system, combining the latest wearable health monitors with sophisticated software tools.

Health Gauge has now secured three key strategic partnerships to assist it in addressing FDA requirements for entry into the U.S. marketplace: Zi Medical, MedStack & Privacy Horizon

With their support, Health Gauge can penetrate the $245bn global digital health monitoring market, continuing its strategy of partnering with leading channel partners, health benefits providers and end-users, via its proprietary combination of:
 

  • digital health monitoring devices,
  • AI-based software, and
  • cloud computing platform.

The company also completed over-subscribed strategic financing for total gross proceeds of $3m. So it is firing on all cylinders!

Make time to watch this one over the long weekend. Tim Daniels, AI/ML Innovations’ Executive Chairman, breaks it all down:

KWESST Micro Systems Announces Results of 2021 Annual General and Special Meeting of Shareholders $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 8:44 AM on Thursday, April 1st, 2021

Ottawa, Ontario–(April 1, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (“KWESST” or “the Company”) announces the results of its 2021 Annual and Special Meeting of shareholders held on Wednesday, March 31, 2021 in virtual format.

Shareholders approved all the resolutions detailed in the management information circular of the Company dated February 11, 2021, namely:

  • Electing all the nominees to the Board of Directors of the Company;
  • Appointing KPMG LLP as auditor of the Company for the ensuing year and authorizing the directors to determine the auditor’s compensation; and,
  • Approving the Company’s long term incentive plan.

The Company also provided the following general business update to investors.

Current contract with U.S. military for TASCS IFM product

The Company reported that it is progressing on schedule and to budget in the delivery of its $1.1M contract for TASCS (Tactical Awareness Situational Control System) IFM (Integrated Fires Module) systems for the 81mm mortar to a key U.S. military customer.

In March 2021, KWESST announced the successful integration of TASCS IFM into the Android Tactical Assault Kit (ATAK), the pre-eminent battlefield management system used by more than a dozen U.S. government agencies and many NATO allies and partner nations.

This integration opens the door to further deployment of the Company’s systems to military customers. The Company will now proceed to the next phase of the contract, involving live-fire trials at various U.S. military bases with full delivery of the contract expected in the current fiscal year.

Progress on other product introduction to the marketplace

GreyGhostTM

GreyGhostTM is a drone whose principal function and operation is acting as a projectile to intercept aerial threats using kinetic (i.e. motion-related) force. GreyGhostTM addresses a concern for deployed military and many security agencies arising from the proliferation of small drones and the potential hazards they pose to troops, sensitive infrastructure and the public at large.

Current methods to tackle this concern include electronic counter-measures which attempt to disrupt communication protocols. Other systems, such as net capture, have a short range and can only deal with one target at a time. The Company’s licensed micro-drone missile technology provides a kinetic interceptor to engage drones threats. With a range in excess of three kilometers, the Company’s GreyGhostTM locks on to a target. Once in attack mode, it will track and repeatedly impact the target drone until it is destroyed. Multiple GreyGhostTM missiles can be launched concurrently to deal with multiple targets simultaneously.

The Company reported that GreyGhostTM is among a small handful of counter-measures against small drones recently down-selected by the U.S. military joint program for further evaluation.

PhantomTM

PhantomTM is a compact, lightweight and selectively electromagnetic transmitter capable of mimicking the electromagnetic footprint of a tactical military units. Recent interest from NATO agencies and defence contractors for this product has resulted in KWESST moving up the production of demonstration samples of PhantomTM in the Company’s priorities.

Non-Lethal Low Energy Cartridge (LEC) System

KWESST management reminded shareholder that the acquisition of the Non-Lethal Low Energy Cartridge (LEC) System is expected to close shortly and KWESST has begun plans to implement rapid productization. For further details on the proposed acquisition, please refer to the Company’s January 18, 2021 and March 23, 2021 news releases.

The LEC system is a proprietary non-lethal cartridge-based ordnance system developed by David Luxton the Executive Chairman of KWESST. The LEC system is a novel proprietary combination of cartridges that fire from a dedicated firing device, with a range of projectile payloads specific to the intended application. The LEC system comprises three main aspects: (i) a dedicated firing platform in a non-standard calibre to ensure “live fire exclusion” for safety; (ii) a non-lethal low energy cartridge case and actuator; and (iii) a non-lethal polymer projectile with various payloads depending on the intended application (public order, training, personal defence or high-action gaming). The calibration of energy dynamics between the firing platform, the energy in the cartridge and the velocity of the projectile combine to ensure reliable functioning of the firing platform and terminal effects that are non-lethal. There are two versions of the LEC cartridge: (i) one for non-reciprocating firing platforms that look like revolvers and shotguns; and (ii) one for reciprocating firing platforms that look like automatic pistols, sub-machine guns and assault rifles.

Active contract pursuits and government funding proposals

The Company reported increased activity in contract proposals and government funding applications. “While we are not able to control the certainty or timing of contracts and funding, we are hopeful that a good portion of our recent efforts will mature in our current fiscal year,” said Jeff MacLeod, KWESST Founder, President and CEO.

Incremental near-term revenue from ATAK Centre of Excellence

“As announced on March 30, we also expect an incremental revenue contribution starting in this fiscal year from our ATAK Centre of Excellence,” said MacLeod. “Some of this work has already begun and we are ramping up to service more government agencies and defence companies who have approached us to develop and support their ATAK applications.”

Industrial Tax Benefits (ITB) credit (typically known outside Canada as “Offsets”)

In a new development, the Company reported that it has begun discussions with a major foreign defence contractor for near-term and potential future defence program work under which the contractor could receive favorable ITB credits for inclusion of KWESST in its supply chain. This has the potential to accelerate and expand the Company’s stated go-to-market strategy of partnering with large defence contractors.

Read More: https://agoracom.com/ir/Kwesst/forums/discussion/topics/758375-kwesst-micro-systems-announces-results-of-2021-annual-general-and-special-meeting-of-shareholders/messages/2310576#message

Liquid Avatar $LQID Joins Good Health Pass Collaborative to Support Open Standard Digital Health Passes $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 8:38 AM on Thursday, April 1st, 2021

Company joins collaboration with industry leaders to help define recommendations for verification of health status to safely restore international travel and restart the global economy.

  • Announced that it has joined the Good Health Pass Collaborative.
  • A project of ID2020, the Good Health Pass Collaborative is an open, inclusive, cross-sector initiative formed to create a blueprint for interoperable digital health pass systems that offer a path to restoring global travel and restarting the global economy.

TORONTO, ON / April 1, 2021 / Liquid Avatar Technologies Inc. (CSE:LQID)(OTC PINK:TRWRF)(FRA:4T51) a global blockchain, digital identity and fintech solutions company and a steering committee member of the Trust Over IP Foundation (ToIP), an independent project for building global digital trust infrastructure hosted by the Linux Foundation, as well as founding member of the Lumedic Exchange, is pleased to announce that it has joined the Good Health Pass Collaborative. A project of ID2020, the Good Health Pass Collaborative is an open, inclusive, cross-sector initiative formed to create a blueprint for interoperable digital health pass systems that offer a path to restoring global travel and restarting the global economy.

In the face of the global COVID-19 pandemic, governments have limited most individual’s ability to work, travel and engage in previously normal everyday activities. As vaccines become more pervasive, and people begin the process of returning to public life, individuals are in need of a way to safely and privately prove that they have tested negative and/or have been vaccinated against the virus.

The Good Health Pass standards will enable airlines, airports, hospitality industries, international customs officials, and others to process visitors easily without requiring additional unnecessary steps mandated by proprietary systems. With uniform standards for travel in place, travelers won’t be confused about which credential they need for each venue and they’ll be in full control of their own personal data. This will give them peace of mind, knowing that access to their private health information is protected and they are able to travel more freely.

“We’re excited to join other industry leaders to provide a highly trusted verifiable credential that will support the global recovery,” said RJ Reiser, Chief Business Development Officer – Liquid Avatar. “By leveraging existing Open Standards, we can support user privacy concerns and empower them with the ability to share what they want, when they want and with whom they want.”

Liquid Avatar has joined the Good Health Pass Collaborative and other organizations so that the Company remains at the forefront of the development of technology and institutional initiatives that will provide our users with the ability to manage, control and benefit from having verifiable credentials that support digital identity programs.

Liquid Avatar is well underway with its building of its verifiable credentials ecosystem that will support this initiative and others by providing users with the ability to store and manage their online credentials and digital identity products.

If you would like to join our mailing list and receive updates from the Company, please click here

About the Good Health Pass Collaborative – www.goodhealthpass.org

The Good Health Pass Collaborative is an open, inclusive, cross-sector initiative to create a blueprint for interoperable digital health pass systems that will help restore global travel and restart the global economy.

Launched in February of 2021 as project of ID2020, the Good Health Pass Collaborative brings together companies and organizations from the health, travel and technology industries with governments and civil society organizations to ensure that digital health pass systems are privacy protecting, user-controlled, interoperable, widely accepted for international travel, and more.

Read More: https://agoracom.com/ir/LiquidAvatar/forums/discussion/topics/758374-liquid-avatar-joins-good-health-pass-collaborative-to-support-open-standard-digital-health-passes/messages/2310575#message

PyroGenesis $PYR Appoints European Investor & Corporate Relations Advisor $RTN $NOC $UTX $DDD.ca $HPQ.ca

Posted by AGORACOM-JC at 8:00 AM on Thursday, April 1st, 2021
  • Appointed DGWA, the German Institute for Asset and Equity Allocation and Valuation (“Deutsche Gesellschaft für Wertpapieranalyse GmbH”, “DGWA”), a German investment banking boutique, as its Investor and Corporate Relations advisor in Europe, effective as April 1 st , 2021 for a period of twelve (12) months.
  • DGWA’s management team has a 25-year track record in trading, investing, and analyzing SMEs around the world.
  • Based in Frankfurt and Berlin, Germany, the company has been involved in more than 250 IPOs, financings, bond issues, dual listings, and corporate finance transactions as well as road shows and awareness campaigns.

MONTREAL, April 01, 2021 – PyroGenesis Canada Inc. (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY) (the “Company” or “PyroGenesis”), a high-tech Company that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, has appointed DGWA, the German Institute for Asset and Equity Allocation and Valuation (“Deutsche Gesellschaft für Wertpapieranalyse GmbH”, “DGWA”), a German investment banking boutique, as its Investor and Corporate Relations advisor in Europe, effective as April 1 st , 2021 for a period of twelve (12) months.

In consideration of the services to be provided, the Company has agreed to pay DGWA a monthly retainer fee payable on the 15 th business day (Germany) of each month. The Company may terminate the Agreement with DGWA, at any time, upon presentation of a forty-five (45) days’ notice. DGWA does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest.

DGWA’s management team has a 25-year track record in trading, investing, and analyzing SMEs around the world. Based in Frankfurt and Berlin, Germany, the company has been involved in more than 250 IPOs, financings, bond issues, dual listings, and corporate finance transactions as well as road shows and awareness campaigns.

PyroGenesis has appointed DGWA to help increase awareness of PyroGenesis’ proprietary advanced plasma technology both within the European financial community as well as with the industry.

“We are delighted to be working with DGWA to increase our visibility within the European financial markets, and also raise awareness of our product offerings amongst potential clients in Europe,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “Our sales growth and momentum in backlog, which should drive near-term profitability, paired with our commitment to green manufacturing while helping mining and metallurgical companies meet their carbon-neutrality goals, matches the expectations of sustainability conscious European investors and stakeholders.”

“We are excited to introduce the PyroGenesis investment opportunity and product offerings to European shareholders and industry players alike.”, adds Mr. Stefan Müller, CEO of DGWA. “The commitment of the company to sustainable development, paired with the booming demand in high-quality, stock exchange listed 3D printing companies are in the favour of growth driven retail as well as institutional investors in Europe.”

Read More: https://agoracom.com/ir/PyroGenesisCanada/forums/discussion/topics/758367-pyrogenesis-appoints-european-investor-corporate-relations-advisor/messages/2310563#message

ImagineAR $IP.ca $IPNFF Selected by 13 Sports Organizations and Media Broadcasters on Hype Sports Innovation Draft Day $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:54 AM on Thursday, April 1st, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

ImagineAR Selections Include Sinclair Broadcast Group, Rogers Sports & Media, Vegas Knights, Philadelphia Phillies, Minnesota Vikings

  • Announced that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021
  • HYPE Sports Innovation has built the largest global ecosystem in sports innovation.
  • With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.

VANCOUVER, BC and ERIE, Pa. , April 1, 2021 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses and enterprises to instantly create their own AR mobile campaigns, is pleased to announce that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021 .

“Today’s Hype Sports Innovation Draft Day was a historic event for the stakeholders of ImagineAR that goes beyond the selection of 13 rights holders representing a worldwide list of sports federations, teams, and media broadcast groups,” said Neal Bendesky , ImagineAR’s VP of Sports. “We are appreciative to Ryan McCumber and the Hype team for offering this unique opportunity for emerging start-ups to help these partners to adjust and innovate after the pandemic.  Our augmented reality platform is an effective tool to assist the sports, music, retail and entertainment industries imagine and adapt to blaze a new trail for their business models.  Thanks to Hype, we can now grow our brand and activate AR solutions for worldwide clients including:”

NFL: Minnesota Vikings
MLB: Philadelphia Phillies
NHL: St. Louis Blues , Vegas Golden Knights
World Governing Body of Cricket: International Cricket Council (ICC)
World Governing Body of Football: Deutscher Fußball-Bund (DFB)
Bundesliga: 1. FC Koln
Leading provider of Local Sports & News ( USA ): Sinclair Broadcast Group
Leading provider Mass Media & Sports Properties ( Canada ): Rogers Sports & Media
Serie A (Top flight of Italian Football): Bologna FC
Uruguayan Primera Division: C.FdeF
MLS & USL: Inter Miami
Categoria Primera A: Atletico Nacional

HYPE Sports Innovation has built the largest global ecosystem in sports innovation. With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.

GrubHub WebAR Live Streaming Concert with Megan Thee Stallion
(Billboard March 29, 2021 )

As per the Billboard Article published on March 29, 2021 , ‘ Megan Thee Stallion , Noah Cyrus and King Princess Take Over GrubHub Sound Bites Interactive Concert’ , Noah Cyrus , King Princess and Megan Thee Stallion came together for GrubHub Sound Bites’s first-ever immersive AR livestream concert. The free event, which virtually took place on March 26 , honored Women’s History Month and World Central Kitchen.

As part of the ImagineAR experience, fans were encouraged to scan customized QR codes that appeared throughout the show to receive special discounts and perks. Those included a chance to win a meet-and-greet with each artist, seeing behind-the-scenes footage, winning a $5 perk to place orders and chances to win a GrubHub gift card.

Within the first 48 hours following the livestream, over 10 million viewers have engaged with the content while driving over 160k interactions from the QR’s scan engagement.

“This was ImagineAR’s first successful WebAR event for First Tube Media and probably the biggest music live streaming WebAR event in history” according to Alen Paul Silverrstieen, CEO of ImagineAR.

ImagineAR Issues Stock Options to Directors and Officers

Imagine AR announces that on April 1, 2021 the Company granted 1,500,000 stock options to directors and officers of the Company.  These stock options are granted in accordance with the terms of the stock option plan of ImagineAR Inc.  The options will vest 50% on the date of grant with the remainder vesting in 90 days and each option entitles the holder thereof to purchase one (1) common share of ImagineAR Inc. at a price of $0.41 per common share for a period of three (3) year.

PyroGenesis $PYR Announces 2020 Results: Revenues $17.8MM; Net Earnings and Comprehensive Income $41.8MM Gross Margin 58%; Current Backlog $30MM; Basic EPS $0.28

Posted by AGORACOM-JC at 10:45 PM on Wednesday, March 31st, 2021
  • Revenues of $17,775,029, an increase of 269% over $4,813,978 posted in the prior year,
  • Net earnings and comprehensive income of $41,768,404 an increase of $50,939,521 over 2019,
  • Net earnings and comprehensive income from operations (before share-based expenses) of $2.9MM during fiscal year 2020 vs ($7.9MM) posted over the same period in 2019,
  • Gross margin of 58%, an increase of 21% year over year,
  • Cash and cash equivalents at December 31, 2020 of $18,104,899 (December 31, 2019: $34,431),
  • Backlog of signed contracts of $30MM,
  • Basic Earnings per Share (EPS) of $0.28 for 2020 as compared to ($0.07) in 2019,
  • Total Assets at December 31, 2020 of $74.5MM (December 31, 2019: $9.6MM),
  • Shareholders’ Equity at December 31, 2020 of $59.4MM (December 31, 2019: ($6.1MM)).

MONTREAL, March 31, 2021 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA:8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce today its financial and operational results for the fourth quarter and fiscal year ended December 31 st , 2020.

“We are happy to announce Q4, and fiscal year end, results for the period ending December 31 st , 2020, which continue the historical trends began earlier in the year. Our full year revenues of $18MM reflects the successful processing of backlog from signed contracts previously disclosed. The Board’s choice of strategy has been validated with the reporting of the second profitable quarter in a row. Further validating this strategy, net income from operations (before share-based expenses) was $3.3MM for the year which is quite significant given the uncertain environment that 2020 was, and during which the Company not only retired virtually all of its debt, but also uplisted to the Toronto Stock Exchange and positioned itself for a NASDAQ listing in Q1 2021,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “The successes of 2020, when combined with the results from our strategic investment, have contributed to a basic EPS of $0.16 for the quarter, and $0.28 for the year, both of which have exceeded previous guidance. With a strong balance sheet and approx. $27MM of cash-on-hand as at this writing, the Company is well positioned to execute on its strategy of growth and solidify its position as an emerging leader in the reduction of greenhouse gas emissions, and as such, we expect these trends established in 2020 to continue.”

2020 results reflect the following highlights:

  • Revenues of $17,775,029, an increase of 269% over $4,813,978 posted in the prior year,
  • Net earnings and comprehensive income of $41,768,404 an increase of $50,939,521 over 2019,
  • Net earnings and comprehensive income from operations (before share-based expenses) of $2.9MM during fiscal year 2020 vs ($7.9MM) posted over the same period in 2019,
  • Gross margin of 58%, an increase of 21% year over year,
  • Cash and cash equivalents at December 31, 2020 of $18,104,899 (December 31, 2019: $34,431),
  • Backlog of signed contracts of $30MM,
  • Basic Earnings per Share (EPS) of $0.28 for 2020 as compared to ($0.07) in 2019,
  • Total Assets at December 31, 2020 of $74.5MM (December 31, 2019: $9.6MM),
  • Shareholders’ Equity at December 31, 2020 of $59.4MM (December 31, 2019: ($6.1MM)).

OUTLOOK

Given the success over the last 18 months, PyroGenesis is well positioned, with a clean balance sheet, and approx. $27 million cash-on-hand (as of this writing), to execute on all its organic growth strategies as well as actively pursuing growth through synergistic merger and acquisitions.

PyroGenesis has recently focused, and repositioned its offerings, to highlight the GHG emissions reduction benefits associated with the majority of its products. Interestingly enough, PyroGenesis’ product lines do not generally need to incorporate GHG/environmental benefits to make sense economically. In other words, they do not require GHG/environmental incentives (tax credits GHG certificates, environmental subsidies) to make sense from a business perspective. We believe these incentives will be a tailwind that will add directly to shareholder value.

We consider this repositioning to be timely as many governments around the world are considering stimulating their respective economies by promoting environmental technologies. As such, Management expects that this repositioning will result in increased revenues.

Organic Growth:

Organic growth will be spurred on by (i) the natural growth of our existing offerings which can now be accelerated given our strong balance sheet and (ii) leveraging off our “Golden Ticket” advantage.

We have described in the past our Golden Ticket advantage as one which occurs when one sells directly, or is engaged directly, with the end user and, as a result, is “inside the fence”. A Golden Ticket affords the opportunity to either, (i) cross sell other products or, ideally, (ii) identify new areas of concern that can be addressed uniquely by PyroGenesis. We call the latter our Coffee and Donuts strategy (if you are selling coffee you could generate additional revenues, with little additional effort, by adding on donuts).

Over the past several years, PyroGenesis has successfully positioned each of its business lines for rapid growth by strategically partnering with multi-billion-dollar entities. These entities have identified PyroGenesis’ offerings to be unique, in demand, and of such a commercial nature as to warrant such unique relationships. We expect that these relationships are now positioned to transition into significant revenue streams.

DROSRITE™

Within the DROSRITE™ offering, the Company is aggressively exploring horizontal growth opportunities. The Company is currently bidding on an RFQ, valued at approx. $40MM (estimated award date: within 4 months; estimated time to completion: approx. 15 months). Management notes that it has been very successful in the selection process to date, but does not yet consider it to be a high-probability outcome at this stage, and provides such as an example of its commitment to this strategy.

Additive Manufacturing

With respect to our Additive manufacturing offering, we expect to see significant year over year improvements in our 3D metal powders offering as our production kicks into gear by incorporating all the previously disclosed benefits (increased production rates, lower capex, lower opex) locked into our production line. There are major top tier aerospace companies and OEMs in both Europe and North America eagerly awaiting powders from this new state of the art production line. Whereas in the past we have been primarily targeting the very demanding Aerospace industry, we have recently expanded the target market to also address the unique needs of the electric vehicles marketplace who have recently approached us with their powder needs.

Plasma Torches

With respect to the Company’s plasma torch offerings, we expect this offering to be significantly impacted by continued developments in the iron ore pelletization industry, where serious consideration is being given to replacing the fossil fuel burners, currently being used throughout the industry, with PyroGenesis’ proprietary plasma torches, in an effort to reduce their carbon footprint.

To date, everything is proceeding as expected. Initial discussions have evolved into confirmation stages which typically consist of a computer simulation followed by a small torch order. These confirmation stages are expected, if successful, to result with a roll-out program to replace fossil fuel burners with PyroGenesis’ plasma torches in the iron ore pelletization industry, in which PyroGenesis is patent protected.

PyroGenesis is proactively targeting other industries which are experiencing significant pressure to reduce GHGs, and which utilize fossil fuel burners as well.

Separately, the Company also offers plasma torches to niche markets where there is a high probability of on-going sales from successful implementation. One such example is the previously announced contract with a small company to produce a plasma torch ideal for tunnelling. PyroGenesis is currently re-evaluating its relationship with respect to this opportunity as there may be evidence that the real plasma-based tunnelling opportunity could lie outside of the scope of the current agreement.

As sales of PyroGenesis’ plasma torches increase, the Company will also benefit from providing proprietary spare parts from which the Company expects to generate significant recurring revenue, thus complementing the Company’s long-term strategy to build upon a recuring revenue model.

HPQ/PUREVAP™

With respect to HPQ, the goal is expanding our role as HPQ technology provider for the game changing PUREVAP™ family of silicon processes which we are developing exclusively for HPQ and its wholly owned subsidiary HPQ Nano Silicon Powders Inc, namely:

  • The PUREVAP™ “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which should permit the one step transformation of lower purity quartz (SiO2) than any traditional processes can handle into a silicon (Si) of a higher purity level (2N-4N) that can be produced by any traditional smelter, at reduced costs, energy input, and carbon footprint. The unique capabilities of this process could position HPQ as a leading provider of the specialized silicon material needed to propagate its considerable renewable energy potential; and
  • The PUREVAP™ Nano Silicon Reactor (NSiR), which, if successful, could position itself as a new proprietary low-cost process that can transform the silicon (Si) made by the PUREVAP™ QRR into the nano-silicon materials (spherical silicon powders and silicon nanowires) sought after by energy storage, batteries, electric vehicle manufactures and clean hydrogen sectors participants. The aim of the ongoing work is to position HPQ NANO as the first to market with a commercial scale low-cost nanoparticle production system.

We expect 2021 to be a year in which significant development occurs on both these fronts.

Growth through Synergistic Mergers and Acquisitions:

As previously disclosed, the Company would conservatively consider a synergistic M&A strategy to augment its growth, and the Company has been very actively involved in pursuing several opportunities in support of this strategy. In so doing, the focus has been on private companies exclusively which (i) primarily leverage the Company’s Golden Ticket advantage/Coffee & Donuts strategy or (ii) could uniquely benefit from the Company’s engineering advantage and/or international relationships.

The Company expects to be announcing specific details over the next few weeks as these opportunities become more binding on the parties involved.

DROSRITE™

We expect to be able to announce within the next several weeks, the conclusion of a joint venture relationship with an existing and proven technology provider. The technology is geared to uniquely handle the residues resulting from the processing of dross in the aluminum industry. We had previously announced our intention to secure this technology and, if concluded, would not only make our traditional DROSRITE™ offering more appealing but could also be offered as a stand-alone product. We believe that valorizing the residues and producing high end products will further define us as the go-to company for all dross related processing. This is a prime example of our Coffee & Donuts strategy in play. For further clarity, the joint venture will only relate to the new technology and, as such, PyroGenesis will not have to vet in any assets, or IP (specifically not the DROSRITE™ technology).

Plasma Torches

PyroGenesis often considers opportunities to leverage its plasma expertise and has been reviewing a torch technology which could complement PyroGenesis’ existing offerings, and leverage off of our unique relationships. The Company gives this a very low probability of success given the initial valuation, provided by the sole owner, in the context of publicly available data. However, PyroGenesis has identified similar opportunities and will evaluate them in due course.

Complimentary

The Company expects to announce in the next several weeks details regarding its intent to enter the Renewable Natural Gas (RNG) market via acquisition. PyroGenesis believes that it is in a unique position to take advantage of the lack of sufficient players (given anticipated demand) in the RNG marketplace by leveraging its engineering capabilities & existing relationships.

In conclusion, PyroGenesis is well positioned in 2021 to take advantage of its unique position in its four main business offerings to accelerate growth in each, with a particular emphasis on offerings geared to aggressively reducing GHG emissions. Furthermore, we do not expect at this point in time, given our strong balance sheet, a need to raise capital to execute on our growth strategy over the foreseeable future.

Financial Summary

Revenues

PyroGenesis recorded revenues of $17,775,029 for the year ended December 31, 2020, representing an increase of 269% compared to $4,813,978 recorded in 2019.

Revenues recorded in fiscal 2020 were generated primarily from:

 (i)PUREVAP™ related sales of $4,163,059 (2019 – $525,556)
 (ii)DROSRITE™ related sales of $9,976,696 (2019 – $560,916)
 (iii)support services related to systems supplied to the US Military $1,425,883 (2019 – $637,841)
 (iv)torch related sales of $1,452,455 (2019 – $2,323,351)
 (v)other sales and services $756,936 (2019 – $766,314)

PUREVAP™ related sales includes revenue from the sale of technologies in the amount of $3,610,000.

Cost of Sales and Services and Gross Margins

Cost of sales and services before amortization of intangible assets was $7,445,171 in 2020, representing an increase of 113% compared to $3,495,753 in 2019, primarily due to an increase in subcontracting, direct materials, an increase in foreign exchange charge on materials offset by a decrease in employee compensation, and investment tax credits.

In 2020, employee compensation, manufacturing overhead & other decreased to $1,886,854 (2019 – $2,230,361). Of note, the Company in 2020 applied for an amount of $775,967 in wage subsidy from Revenue Canada under the CEWS “Canada Emergency Wage Subsidy” program. From this amount, $118,416 was applied to employee compensation under cost of sales and services. Subcontracting and direct materials increased to $5,429,175 (2019 – $1,471,226), primarily due to the increased amount of contract values.

The gross margin for 2020 was $10,302,668 or 58% of revenue compared to a gross margin of $1,298,092 or 27% of revenue for 2019. As a result of the type of contracts being executed, the nature of the project activity had a significant impact on the gross margin and the overall level of cost of sales and services reported in a period, as well as the composition of the cost of sales and services, as the mix between labour, materials and subcontracts may be significantly different. The cost of sales and services for 2020 and 2019 are in line with Management’s expectations. The gross margin includes the full effect of the sale of intellectual property and royalties of $3,610,000 in 2020. Excluding the effect of this revenue, the gross margin for 2020 would have been 47.2%.

Investment tax credits recorded against cost of sales are related to projects that qualify for tax credits from the provincial government of Quebec. Qualifying tax credits decreased to $18,420 in 2020, compared to $179,670 in 2019. The decrease is primarily related to fewer contracts being eligible for qualifying tax credits.

The amortization of intangible assets of $27,190 in 2020 and $20,133 for 2019 relates to patents and deferred development costs. Of note, these expenses are non-cash items and will be amortized over the duration of the patent lives.

Selling, General and Administrative Expenses

Included within Selling, General and Administrative expenses (“SG&A”) are costs associated with corporate administration, business development, project proposals, operations administration, investor relations and employee training.

SG&A expenses for 2020 excluding the costs associated with share-based compensation (a non-cash item in which options vest principally over a four-year period), were $8,089,945, representing an increase of 34% compared to $6,017,091 reported for 2019.

The increase in SG&A expenses in 2020 over the same period in 2019 is mainly attributable to the net effect of:

 (i)an increase of 79% in employee compensation primarily due to additional head count, an increase in commissions, bonuses, offset by an amount of $504,339 received from Revenue Canada under the CEWS program.
 (ii)an increase of 14% for professional fees, primarily due to an increase in legal fees, public listing fees and patent expenses,
 (iii)an increase of 12% in office and general expenses, is primarily due to computer, internet, and security expenses,
 (iv)travel costs decreased by 71%, due to a decrease in travel abroad,
 (v)depreciation on property and equipment decreased by 63% due to lower amounts of property and equipment being depreciated,
 (vi)depreciation on right of use assets increased by 13% due to higher amounts of right of use assets being depreciated,
 (vii)investment tax credits were almost the same year to year, and include the recognition of investment tax credits in the amount of $30,000,
 (viii)government grants decreased by 4%, due to lower levels of activities supported by such grants,
 (ix)other expenses decreased by 8%, primarily due to an increase in advertising, interest and bank expenses,
 (x)the tax assessment in 2019, represents the amount due from a taxation audit for the period of 2008 to 2011. The Company paid royalties for the use of intangible property prior to the purchase of the asset. The royalties were subject to a 25% withholding tax that was not deducted or withheld by the Company at that time.

Separately, share based payments increased by $4,072,801 in 2020 over the same period in 2019 as a result of the stock options granted on July 16, 2020. This was directly impacted by the vesting structure of the stock option plan with options vesting between 25% and 50% on the grant date requiring an immediate recognition of that cost.

Research and Development (“R&D”) Costs

The Company incurred $775,824 of R&D costs less $1,033,412 of investment tax credits which reduce income taxes payable in current year less $24,605 of investment tax credit refund from previous year, less $83,451 of 2020 eligible investment tax credits, less government grants of $365,433 totaling a net R&D cost of ($731,077), on internal projects in 2020, a decrease of 186% compared to $851,512 in 2019. The decrease in 2020 is primarily related to an increase of labor resources allocated to non research and development contracts.

In addition to internally funded R&D projects, the Company also incurred R&D expenditures during the execution of client funded projects. These expenses are eligible for Scientific Research and experimental Development (“SR&ED”) tax credits. SR&ED tax credits on client funded projects are applied against cost of sales and services (see “Cost of Sales” above).

Net Finance Costs

Finance costs for 2020 totaled $524,074 as compared with $1,237,504 for 2019, representing a decrease of 58% year-over-year. The decrease in finance costs, is primarily attributable to the extinguishment of all term loans, other loans, and convertible debentures in 2020.

Strategic Investments

The adjustment to the fair market value of strategic investments in 2020 resulted in a gain of $44,626,698 compared to a gain in the amount of $176,237 in 2019, representing an increase of $44,450,461. The increase is primarily attributable to the increased market share value of common shares and warrants owned by the Company of HPQ Silicon Resources Inc.

Net Earnings and Comprehensive Income (Loss)

 (i)an increase in product and service-related revenue of $12,961,051 arising in 2020,
 (ii)an increase in cost of sales and services totaling $3,956,475, primarily due to higher subcontract costs, and direct materials as a result of an increase in contracts in 2020,
 (iii)an increase in SG&A expenses not including share-based expenses of $2,072,854 arising in 2020 primarily due an increase in employee commissions and bonuses,
 (iv)a decrease in R&D expenses of $1,582,589 primarily related the recognition of investment tax credits in 2020 and prior years in the amount of $1,141,468 which include amounts that reduce Canadian income taxes payable in 2020 and an amount of $365,433 in government grants,
 (v)a decrease of $1,981,410 in 2020 due to impairment of a Plasma Atomization 2019. The Company commenced construction on a new and improved Plasma Powder Production equipment,
 (vi)a decrease of $386,121 in 2020 due to the write off, of powders and raw materials inventory in 2019,
 (vii)an increase in share-based expense of $4,072,801,
 (viii)an increase in changes in fair market value of strategic investments and net finance costs of $45,163,891,
 (ix)an increase in income taxes of $1,033,412

EBITDA

The EBITDA in 2020 was $43,824,533 compared to an EBITDA loss of $7,384,862 for 2019, representing an increase of 693% year-over-year. The increase in the EBITDA in 2020 compared to 2019 is due to the increase in net earnings and comprehensive income of $50,939,520, offset by a decrease in depreciation on property and equipment of $105,717, an increase in depreciation on right-of-use assets of $48,552, an increase in amortization of intangible assets of $7,057, a decrease in finance charges of $713,431 and an increase in income taxes of $1,033,412.

Adjusted EBITDA in 2020 was $48,069,141 compared to an Adjusted EBITDA loss of $4,845,524 for 2019. The increase of $52,914,665 in the Adjusted EBITDA in 2020 is attributable to an increase in EBITDA of $51,209,395, an increase of $4,072,801 in share-based payments, a decrease in inventory write-off of $386,121, and a decrease in equipment write-off of $1,981,410.

The Modified EBITDA in 2020 was $3,442,443 compared to a Modified EBITDA loss of $5,021,761 for 2019, representing an increase of 169%. The increase in the Modified EBITDA in 2020 is attributable to the increase as mentioned above in the Adjusted EBITDA of $52,914,665 and an increase in chance of fair value of investments of $44,450,461.

Liquidity

As at December 31, 2020, the Company has cash and cash equivalents of $18,104,899. In addition, the accounts payable and accrued liabilities of $4,708,051 are payable within 12 months. The Company expects that its cash position will be able to finance its operations for the foreseeable future.

On November 3, 2020, the Company closed a bought-deal short form prospectus offering of 3,354,550 units at a price of $3.60 per unit for aggregate gross proceeds to the Company of $12,076,380, including the full exercise of the over-allotment option. In connection with the offering, the Company paid $1,934,154 in cash and issued 191,414 compensation options. Each compensation option entitles the holder thereof to purchase one unit at a price of $3.60 until November 10, 2022. Each unit is comprised of one common share of the Company and one-half of one common share purchase warrant of the company. Each warrant entitles the holder to purchase one additional common share at an exercise price of $4.50 for a period of 24 months.

At December 31, 2020, there have not been any material uses of the proceeds received from the offering.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.sec.gov. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the NASDAQ Stock Market, LLC accepts responsibility for the adequacy or accuracy of this press release.

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.

References:

  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.